Navigation Links
Regado Biosciences Completes Patient Enrollment for Phase IIa Study of REG1 Anticoagulation System
Date:10/14/2008

DURHAM, N.C., Oct. 10 /PRNewswire/ -- Regado Biosciences, Inc., announced today the Company has completed enrollment in the Phase IIa clinical study of its REG1 Anticoagulation System in patients undergoing elective percutaneous coronary intervention (PCI). REG1 is a two-component system composed of an aptamer-based anticoagulant, RB006, and its matched, active reversal agent, RB007, which specifically binds to and neutralizes RB006. The Phase IIa study (REVERSAL-PCI) is designed to assess whether REG1 can replace standard heparin therapy during the performance of coronary balloon angioplasty dilatation and stenting on patients at low risk for complications associated with therapy-related bleeding or heart attack.

REVERSAL-PCI, a multi-center, open-label, randomized clinical study, has enrolled a total of 26 patients. All patients were pretreated with clopidogrel and aspirin to inhibit platelet activity and were then randomized to receive either REG1 or unfractionated heparin. In patients treated with the REG1 System, RB006 was used as the sole anticoagulant during the procedure. Following the procedure, RB007 was used to reverse the effects of RB006 with the goal of facilitating early sheath removal. Primary procedural success in the trial is defined by the absence of significant bleeding events up to hospital discharge or 48 hours post stenting, and by the absence of death, nonfatal heart attack, or need to repeat revascularization up to day 14.

David J. Mazzo, Ph.D., President and Chief Executive Officer of Regado Biosciences, stated, "The Phase IIa trial is designed to build on extensive Phase I results demonstrating, among other things, that RB006 safely and effectively inhibited the activity of factor IXa, an essential blood clotting protein, and that RB007 rapidly, safely and specifically reversed the activity of RB006. We are pleased to have reached this milestone in our clinical program and look forward to continued progress in the comi
'/>"/>

SOURCE Regado Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Regado Biosciences Reports Clinical Results for REG1 Anticoagulation System at European Society of Cardiology Congress 2008
2. Regado Biosciences Announces Publication in Circulation of Clinical Trial Results of REG1 Anticoagulation System
3. Regado Biosciences Presents Early Stage Clinical Data for REG1 Anticoagulation System at American Heart Association 2007 Scientific Sessions
4. Regado Biosciences Presents Positive Data From REG1 Anticoagulation System Phase Ic Study at American Heart Association 2007 Scientific Sessions
5. Regado Biosciences Initiates Phase IIa Clinical Study of REG1 Anticoagulation System
6. Ardea Biosciences Presents Preclinical Anti-Inflammatory Data on its Lead MEK Inhibitor, RDEA119, at the ACG 2008 Annual Meeting
7. Epiphany Biosciences to Continue Phase 2 Shingles Study After Interim Analysis; Plans Follow-On Clinical Trial Studying Post-Herpetic Neuralgia (PHN)
8. Ardea Biosciences to Present Data on Lead MEK Inhibitor, RDEA119, at American College of Gastroenterology Annual Scientific Meeting
9. Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS)
10. Neurocrine Biosciences Announces Successful Elagolix PETAL Study in Endometriosis
11. Ardea Biosciences Advances Lead Product Candidate for the Treatment of Gout, RDEA594, Into Phase 1 Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... Cali ., Aug. 22, 2014  Research presented at ... a therapy being developed by Hera Therapeutics Inc. combats three ... percent of all cervical cancer. When tested in ... HPV-16, HPV-18 and HPV-11 cells, according to Louise T. ... presented the findings at the Seattle ...
(Date:8/22/2014)... - SQI Diagnostics Inc. (TSX-V: SQD), a life ... and products for advanced microarray diagnostics, today announced ... Agreement to contract with a UK-based company to ... initial phase of this agreement, SQI will be ... one of the customer,s assays, operational on SQI,s ...
(Date:8/21/2014)... Nektar Therapeutics (NASDAQ: NKTR ... results from its Phase 3 pivotal clinical trial ... factor VIII (rFVIII) treatment for hemophilia A based ... primary endpoint in reducing annualized bleed rates (ABR) ... arm. Top-line results from the prospective, ...
Breaking Medicine Technology:Study shows Hera Therapeutics experimental compound shuts down human papillomavirus that causes most cervical cancer 2SQI Diagnostics Contracted to Automate Pathogen Detection Assays 2SQI Diagnostics Contracted to Automate Pathogen Detection Assays 3Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 2Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 3Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 4Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 5
... Inc. (NYSE: HSP ), a leading global specialty ... will present at the Morgan Stanley Global Healthcare Conference on ... presentation is scheduled to begin at 8:35 a.m. Eastern time ... all interested parties through a live audiocast accessible via the ...
... Wright Therapy Products, Inc. announced today that ... Executive Officer of the company.  The company, based ... devices targeted for the treatment of lymphedema, venous ... Wright Therapy after holding senior financial and sales ...
Cached Medicine Technology:Industry Leaders Hinson and Friel Join Wright Therapy Products 2
(Date:8/23/2014)... 2014 Dealing with a drug or alcohol ... the addict is a child. Adolescent addiction has been an ... time, but a new helpline is now providing a valuable ... to find a real addiction recovery center. , The Troubled ... impact in the community. By calling (404) 975-2762, parents and ...
(Date:8/22/2014)... (PRWEB) August 23, 2014 Search ... on the first page of search engines and ... SEO Hosting has recently compared many Linux hosting ... and Bluehost are the most recommended Linux hosting ... Australia and Europe to buy high quality Linux ...
(Date:8/22/2014)... Today, Zane Benefits, the #1 Online Health ... Plans. , According to Zane Benefits, employers are adopting ... the cost of healthcare without reducing coverage for employees. ... can be confusing. , The new guide contains a ... types of ABHPs. It also explains the similarities, ...
(Date:8/22/2014)... 23, 2014 This report studies ... Liquid Handling Systems), Consumables (Tubes), Kits (Isolation, Purification), ... Diagnostics) - Global Forecast to 2018" This market ... is poised to grow at a CAGR of ... million by 2018. , Browse 98 market data ...
(Date:8/22/2014)... Recently, iFitDress.com, a well-known wedding dress manufacturer and ... wedding gowns . In addition to this, the company’s ... are provided with low shipping fees. , He ... new wedding gowns. In our online store, there are ... choose from. What’s more, all of them are extremely ...
Breaking Medicine News(10 mins):Health News:Atlanta’s New Troubled Teen Helpline Is Making a Difference in the Community 2Health News:Top10BestSEOHosting.com Announces Best Cheap Hosting Suppliers Of This Summer 2Health News:Sample Preparation Market by Product and Application Worth $5,672 Million by 2018 - New Research Report by MarketsandMarkets 2Health News:Sample Preparation Market by Product and Application Worth $5,672 Million by 2018 - New Research Report by MarketsandMarkets 3Health News:Sample Preparation Market by Product and Application Worth $5,672 Million by 2018 - New Research Report by MarketsandMarkets 4Health News:Discounted Wedding Gowns For Sale At Leading Online Shop iFitDress.com 2
... harbor profound misperceptions about the effects ... designed to help them quit, PITTSBURGH, Nov. 13 ... dangers of smoking over the past 40 years, a ... GlaxoSmithKline,Consumer Healthcare, an industry leader in smoking cessation, indicates,major ...
... Disease & Kennel Cough: Serious, But Avoidable; ... Reputable Pet Sitter, BERKELEY, Calif., Nov. 13 With ... reports regarding the highly,contagious and potentially deadly strains of canine ... cough virus -- have many dog,owners worried. So, what,s a ...
... is the only way,to describe the unsolicited testimonial received this month by ... Because of your service we were there within about ... is already home as of yesterday evening. Your service ... never work for her because when she has an ...
... Inc., a subsidiary of Natural Nutrition Inc. ... made another major,breakthrough in the international market ... Panama. InterACTIVE Nutrition brand high energy protein,products ... department in Panama.,This is a significant achievement, ...
... Today; ... in the United States, LYON, France, November 13 ... it has,signed an exclusive global collaboration agreement with Acambis plc, ... help fight against,this serious, life-altering and potentially fatal disease. Scientists,believe ...
... carbohydrates may help stunt the growth of prostate tumors, according ... The study, in mice, suggests that a reduction in insulin ... , This study showed that cutting carbohydrates may slow tumor ... urologist at Duke University Medical Center and lead researcher on ...
Cached Medicine News:Health News:Smokers Remain Unaware of the Health Effects of Smoking, New Survey Finds 2Health News:Smokers Remain Unaware of the Health Effects of Smoking, New Survey Finds 3Health News:Smokers Remain Unaware of the Health Effects of Smoking, New Survey Finds 4Health News:Smokers Remain Unaware of the Health Effects of Smoking, New Survey Finds 5Health News:Smokers Remain Unaware of the Health Effects of Smoking, New Survey Finds 6Health News:Safeguard Your Pet From Seasonal Ailments 2Health News:Safeguard Your Pet From Seasonal Ailments 3Health News:Sentry Telecare Establishes Partnering Program to Market Telephone Check-in and Personal Emergency Response Service 2Health News:Natural Nutrition Ships First InterACTIVE Nutrition Brand Products to Panama 2Health News:Sanofi Pasteur and Acambis Join Forces to Bring West Nile Vaccine to Market 2Health News:Sanofi Pasteur and Acambis Join Forces to Bring West Nile Vaccine to Market 3Health News:Sanofi Pasteur and Acambis Join Forces to Bring West Nile Vaccine to Market 4Health News:A low-carb diet may stunt prostate tumor growth 2
... The Estriol (unconjugated) enzyme immunoassay (EIA) test ... in vitro,determination of unconjugated estriol in human ... The Estriol (unconjugated) procedure is an enzyme ... competitive binding. In this procedure, estriol is ...
LH EIA Reproductive Markers 025-BC-1031 Luteinizing Hormone...
... based on the competition principle and the ... in the sample and a fixed amount ... for the,binding sites of a polyclonal Estradiol ... hours incubation the microtiterplate is,washed to stop ...
... the most important androgen secreted into the ... the Leydig cells of the testes; in ... derived from,peripheral conversion of androstenedione, ca. 25% ... the adrenal glands. The Testosterone ELISA KIT ...
Medicine Products: